Physician profile
Andrew Weinstein
NPI 1821191099
$197,010.22
in general payments reported to CMS, 2019-2025
38 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $188 · 2021: $617 · 2022: $27K · 2023: $31K · 2024: $48K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Consulting Fee: $68K · Travel and Lodging: $12K · Food and Beverage: $5,245 · Education: $194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,638.53 |
| Consulting Fee | $68,351.95 |
| Travel and Lodging | $12,451.95 |
| Food and Beverage | $5,244.95 |
| Education | $194.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $90,584.46 | 2022-2025 | Libtayo, Dupixent |
| Leo Pharma INC. | $58,432.43 | 2019-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $24,188.92 | 2019-2025 | Blu-U, Odomzo |
| Pfizer INC. | $18,407.99 | 2021-2025 | |
| Organogenesis INC. | $1,252.63 | 2020-2025 | Affinity, Puraply, Cygnus Dual |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $622.08 | 2019 | |
| Abbvie INC. | $575.48 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $477.16 | 2019-2025 | Tremfya |
| Genzyme Corporation | $319.15 | 2019-2025 | |
| Dermavant Sciences, INC. | $299.44 | 2022-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $243.55 | 2019-2025 | |
| Biofrontera INC. | $189.57 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| E.R. Squibb & Sons, L.L.C. | $133.99 | 2023-2025 | Sotyktu |
| Genentech USA, INC. | $119.12 | 2019-2021 | |
| Convatec INC. | $102.09 | 2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Weinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.